Skip Navigation


Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Atopic Dermatitis Research Network

In 2004, NIAID established the Atopic Dermatitis and Vaccinia Network (ADVN) to better understand why some people with atopic dermatitis are at high risk for eczema vaccinatum, a rare and severe adverse reaction to the smallpox vaccine.

In 2010, NIAID expanded the goals of the ADVN and renamed it the Atopic Dermatitis Research Network (ADRN). ADRN scientists aim to understand host defense mechanisms and immune system responses in the skin by comparing responses to viral and bacterial skin infections in healthy individuals with those in people with atopic dermatitis. Ongoing clinical and animal research examines

  • Defense mechanisms of the skin, including immune defenses and the function of the skin as a barrier
  • Immune changes during disease development
  • Genetic variants that contribute to the development and severity of atopic dermatitis
  • Susceptibility to colonization and infection by bacteria such as methicillin-resistant Staphylococcus aureus
  • Susceptibility to infection by viruses, including herpes simplex virus and vaccinia virus
  • Vaccine responses among people with atopic dermatitis.

Learn more about the ADRN.

Last Updated May 15, 2013